Mebendazole for Lung Cancer: Small Cell Data and Microtubule Disruption

The Bottom Line

Mebendazole has demonstrated potent activity against small-cell lung cancer (SCLC) cell lines and non-small cell lung cancer (NSCLC) models. The mechanism, microtubule disruption, is the same approach used by docetaxel and paclitaxel, two standard lung cancer chemotherapy drugs. Mebendazole is not a replacement for these, but the preclinical evidence is strong and it has the advantage of an established human safety profile from decades of antiparasitic use.

The Evidence

Sasaki et al. (Clinical Cancer Research, 2002) showed mebendazole induced mitotic arrest and apoptosis in SCLC cell lines with an IC50 of ~0.16 μM, a clinically achievable concentration.
The ReDO Project (PMC6769799) extensively reviewed mebendazole for cancer repurposing, citing lung cancer preclinical data as one of the strongest signals.
A Phase 2a trial in advanced gastrointestinal cancer (Nature Scientific Reports, 2021) confirmed mebendazole reaches systemic tumor-relevant concentrations in humans at 100-200mg dosing.
No dedicated lung cancer RCT exists yet, but the mechanism and preclinical profile are strong.

Why the Mechanism Matters

Cancer cells must replicate their DNA and physically divide to form new tumor cells. Both steps require functional microtubules, the structural scaffolding that pulls chromosomes apart during cell division. Disrupt microtubules and the cell cannot divide: it stalls in mitosis and dies.

This is exactly how docetaxel and paclitaxel work, and both are first-line treatments for lung cancer. Mebendazole hits the same molecular target, beta-tubulin polymerization, by binding to tubulin and preventing the microtubule polymer from assembling. The key difference is cost and tolerability: docetaxel causes severe neutropenia, hair loss, and fluid retention. Mebendazole, at antiparasitic doses, is well tolerated with decades of safety data in humans.

Beyond microtubule disruption, mebendazole also inhibits VEGFR2, the primary receptor driving tumor angiogenesis. Lung tumors are highly vascularized, and anti-angiogenic therapy is already a validated approach in NSCLC: bevacizumab (Avastin) targets the same pathway. Mebendazole adding VEGFR2 inhibition on top of microtubule disruption gives it two independent mechanisms relevant to lung cancer.

Small Cell vs Non-Small Cell

Small cell lung cancer (SCLC) has the strongest preclinical signal. The Sasaki et al. 2002 study in Clinical Cancer Research was specifically conducted in SCLC cell lines, achieving potent cell kill at concentrations achievable with standard oral dosing. SCLC is a fast-growing, aggressive cancer with fewer treatment options than NSCLC, which means oncologists and researchers are more actively exploring repurposed drugs in this space.

Non-small cell lung cancer (NSCLC) has less direct mebendazole data, but two additional mechanisms are relevant. First, itraconazole has shown 72-79% tumor growth reduction in NSCLC xenograft models (see itraconazole for lung cancer), and both itraconazole and mebendazole inhibit the Hedgehog signaling pathway. Second, mebendazole's VEGFR2 inhibition is directly relevant in NSCLC where angiogenesis drives tumor progression. The mechanisms overlap meaningfully, even where direct NSCLC cell line data is thinner.

Practical Information

Dose: 100-200mg daily, taken with a high-fat meal. Fat increases mebendazole absorption 3-5x and is essential for achieving therapeutic blood levels.
Cost: Generic, approximately $5-15/month depending on supplier and dose.
Safety: Profile well established from decades of antiparasitic use at single-dose and short-course treatment. Long-term daily dosing at cancer-relevant levels requires monitoring.
Monitoring: Liver enzymes (ALT, AST) should be checked periodically if using long-term. Hepatotoxicity is possible at sustained high doses.
Interactions: Discuss with your oncologist before adding mebendazole to any chemotherapy regimen. Drug-drug interactions are possible, particularly with taxane-based chemotherapy targeting the same pathway.
Prescription: Any physician can prescribe mebendazole off-label. It is FDA-approved as an antiparasitic.

Related Research

Sources

PMC6769799: ReDO Project mebendazole review pmc.ncbi.nlm.nih.gov/articles/PMC6769799
Sasaki et al., Clinical Cancer Research 2002: Mebendazole in SCLC cell lines clincancerres.aacrjournals.org/content/8/9/2963
Nature Scientific Reports 2021: Phase 2a trial, mebendazole pharmacokinetics nature.com/articles/s41598-021-88433-y